An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment

Inclusion Criteria:

- Patient is currently enrolled in a Novartis-sponsored, CD&MA study receiving
everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their
requirements in the parent study

- Patient is currently benefiting from treatment with everolimus, as determined by the
guidelines of the parent protocol.

Exclusion Criteria:

- Patient has been permanently discontinued from everolimus study treatment in the
parent study.

- Patient is receiving everolimus in combination with an unapproved or experimental
treatment

- Other protocol-defined inclusion/exclusion criteria may apply